试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
编号:NCT00230607登记状态:提前终止企业 / 申办者:Genzyme, a Sanofi Company
药物 / 成分:agalsidase beta
登记的停止原因(原文):Per FDA decision, the 2003 Post Marketing commitment has been fulfilled.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
Dose of Corticosteroids in COPD
编号:NCT01742338登记状态:提前终止企业 / 申办者:Rutgers, The State University of New Jersey
药物 / 成分:Low Dose Corticosteroids、High Dose Corticosteroids
登记的停止原因(原文):Lack of research staff to recruit participants
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
编号:NCT03056495登记状态:提前终止企业 / 申办者:German Center for Neurodegenerative Diseases (DZNE)
药物 / 成分:N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
登记的停止原因(原文):Insufficient Recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
编号:NCT03103971登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes、Cyclophosphamide、Fludarabine、Laboratory Biomarker Analysis
登记的停止原因(原文):Terminated due to slow enrollment and end of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy
编号:NCT04064697登记状态:提前终止企业 / 申办者:Centre Hospitalier Universitaire de Saint Etienne
药物 / 成分:Valganciclovir
登记的停止原因(原文):low of inclusions
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
编号:NCT04337827登记状态:提前终止企业 / 申办者:Deepa Jagadeesh
药物 / 成分:Rituximab、Acalabrutinib、CT scans
登记的停止原因(原文):Slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
编号:NCT04677855登记状态:提前终止企业 / 申办者:Pellficure Pharmaceuticals, Inc
药物 / 成分:PCUR-101、Dutasteride 0.5 mg、Abiraterone and Prednisone
登记的停止原因(原文):Business Decision due to insufficient enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-10
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
编号:NCT05484011登记状态:提前终止企业 / 申办者:HiberCell, Inc.
药物 / 成分:odetiglucan、CDX-1140
登记的停止原因(原文):sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
编号:NCT01458405登记状态:提前终止企业 / 申办者:Capricor Inc.
药物 / 成分:CAP-1002 Allogeneic Cardiosphere-Derived Cells、Placebo
登记的停止原因(原文):On February 28, 2019, Capricor ceased ongoing follow-up activities and terminated the ALLSTAR trial to focus resourcing on its active CAP-1002 program, HOPE-2.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-04-09
A PhaseI/IIa Study to Determine the Safety and Tolerability of MA09-hRPE Cells in Patients With Advanced Dry AMD
编号:NCT01674829登记状态:提前终止企业 / 申办者:CHABiotech CO., Ltd
药物 / 成分:MA09-hRPE
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗